Table 1.
A selection of ongoing and completed clinical trials employing Ad vectors
| Conditions | Intervention | Transgene | Trial stage | Identifier |
|---|---|---|---|---|
| Prostate cancer | CG7870 combination with Docetaxel | E1A under control of the rat probasin promoter and E1B under control of the PSA promoter-enhancer | Phase I/II | NCT00103428 |
| Prostate cancer | CG7870 | E1A under control of the rat probasin promoter and E1B under control of the PSA promoter-enhancer | Phase I/II | NCT00116155 |
| Metastatic melanoma | OBP-301 (Telomelysin) | E1A/E1B under control of human telomerase reverse transcriptase gene hTERT promoter | Phase II | NCT03190824 |
| Esophagogastric adenocarcinoma | OBP-301 (Telomelysin) | E1A/E1B under control of human telomerase reverse -transcriptase gene hTERT promoter | Phase II | NCT03921021 |
| Solid tumors | Ad/PNP coupled with fludarabine phosphate | PNP | Phase I | NCT01310179 |
| Hormone-refractory metastatic prostate cancer | Ad-OC-TK + valacyclovir | HSV-TK gene under control of osteocalcin promoter in the area of the excised E1 region | Phase I/II | in Japan |
| Prostate cancer | AdV/RSC-TK + Brachytherapy | HSV-TK gene under control of Rous sarcoma virus long terminal repeat promoter RSV | Phase II | NCT01913106 |
| Prostate cancer | CTL102 + CB1954 | NTR under control of CMV promoter | Phase I/II | 40 Patient cohort in UK |
| Advanced pancreatic cancer | Ad5-yCD/mutTK(SR39)rep-ADP | CD/TK/ADP | Phase I | NCT02894944 |
| Prostate cancer | Ad5-yCD/mutTK(SR39)rep-ADP + IMRT intensity-modulated radiation therapy | CD/TK/ADP | Phase I/II | NCT00583492 |
| Prostate cancer | Ad5-yCD/mutTK(SR39)rep-hIL12 | CD/TK/hIL12 | Phase I | NCT02555397 |
| Malignant pleural mesothelioma | rAd-IFN administered with Celecoxib and Gemcitabine | IFN-α-2b | Phase III | NCT03710876 |
| Advanced peritoneal malignancies | Oncos-102 + Durvalumab | GM-CSF | Phase I/II | NCT02963831 |
| Metastatic castration-resistant prostate cancer | Oncos-102 + DCVAC/PCA | GM-CSF | Phase I/II | NCT03514836 |
| High-grade NMIBC after BCG failure | CG0070 | E1A under control of E2F-1 promoter, CM-CSF under control of E3 promoter | Phase II | NCT02365818 |
| Mutiple advanced cancer | LOAd703 | CD40L and 4-1BBL under control of CMV promoter | Phase I/II | NCT03225989 |
| Pancreatic cancer | LOAd703 | CD40L and 4-1BBL under control of CMV promoter | Phase I/II | NCT02705196 |
| Malignant melanoma | LOAd703 + Atezolizumab | CD40L and 4-1BBL under control of CMV promoter | Phase I/II | NCT04123470 |
| Recurrent glioblastoma | DNX-2401 | NA | Phase I | NCT00805376 |
| Recurrent glioblastoma | DNX-2401 + Temozolomide | NA | Phase I | NCT01956734 |
| Recurrent glioblastoma or gliosarcoma brain tumors | DNX-2401 + IFN-γ | NA | Phase I | NCT02197169 |
| Naive diffuse intrinsic pontine gliomas | DNX-2401 | NA | Phase I | NCT03178032 |
| Recurrent high-grade glioma | DNX-2401 | NA | Phase I | NCT03896568 |
| Advanced or metastatic melanoma | ICOVIR-5 (Ad-DM-E2F-K-Delta-24-RGD) | E1A under control of E2F-1 promoter and myotonic dystrophy locus insulator DM-1 | Phase I | NCT01864759 |
| Refractory solid tumors | ICOVIR-7 | E1A under control of E2F-1 promoter with four new E2F-responsive palindromes | 21 Patient cohort in Finland | |
| Advanced pancreatic cancer | VCN-01 + Gemcitabine and Abraxane® | E1A under control of E2F-1 promoter and myotonic dystrophy locus insulator DM-1, and Hyaluronidase | Phase I | NCT02045589 |
| R/M head and neck squamous cell carcinoma | VCN-01 + Durvalumab | E1A under control of E2F-1 promoter and myotonic dystrophy locus insulator DM-1, and Hyaluronidase | Phase I | NCT03799744 |
| Refractory retinoblastoma (RTB) | VCN-01 | E1A under control of E2F-1 promoter and myotonic dystrophy locus insulator DM-1, and Hyaluronidase | Phase I | NCT03284268 |
| Resectable colon cancer, non-small cell lung cancer, bladder cancer, renal cell carcinoma | ColoAd1 (Enadenotucirev) | NA | Phase I | NCT02053220 |
| Locally advanced rectal cancer | Chemoradiation + Enadenotucirev | NA | Phase I | NCT03916510 |
| Metastatic cancer, epithelial tumor | NG-641 | FAP-TAc antibody /CXCL9/CXCL10/IFN-α | Phase I | NCT04053283 |
| Metastatic cancer, epithelial tumor | NG-350A | anti-CD40 antibody | Phase I | NCT03852511 |
CD cytosine deaminase, CD40L CD40 ligand, CMV cytomegalovirus, CXCL chemokine ligand, FAP-Tac fibroblast-activating protein/CD3, GM-CSF granulocyte-macrophage colony-stimulating factor, hIL12 human interleukin-12, HSV-TK herpes simplex virus thymidine kinase, hTERT human telomerase reverse transcriptase, IFN interferon, NA not applicable, NTR Escherichia coli nfsB bacterial nitroreductase, PNP Escherichia coli Pruine nucleoside phosphorylase, PSA prostate-specific antigen.